Can Daewoong’s P-CAB Unsettle Competition?

Company Seeking Partnerships For Markets Such As China And The US

Daewoong Pharmaceutical has successfully completed a Phase III clinical trial of next generation gastroesophageal reflux disease (GERD) drug candidate in South Korea, but strong competition awaits from approved P-CAB drugs of CJ Healthcare and Takeda.

Acid_Reflux
A New P-CAB Drug Candidate On Horizon • Source: Shutterstock

More from R&D

More from Scrip